Effect of Bread Fortified With Portulaca Oleracea on Diabetic Patients with Metabolic Syndrome: A Randomized Clinical Trial
DOI:
https://doi.org/10.22100/jkh.v16i1.2547Abstract
Introduction: Metabolic syndrome is a set of abnormal metabolic factors that put people at greater risk for cardiovascular disease, stroke, osteoporosis, cancer and inflammation. The aim of this study was to evaluate the effect of portulaca enriched bread on diabetic patients with metabolic syndrome.
Methods: This parallel randomized clinical trial was performed on 104 diabetic patients with metabolic syndrome. Patients were divided into intervention and control groups. The intervention group received daily portion of bread enriched with portulaca (10%) and the control group received bread without portulaca oleracea to evaluate the effect of the intervention, the difference between the mean before and after these indices in the two groups was performed using paired t-test.
Results: The mean age of participants was 53.6. 6.5 years and the age range of participants were between 33 and 63 years. Men (51%) were 53 and women (49%) were 51 subjects. 56 (53%) participants had a mean age of 2 years of diabetes, 56 (53.8%) participants were high school literate and 49.8% were illiterate. The results showed that before the intervention, there was a significant difference in the mean of the studied variables except diastolic blood pressure (P <0.01) in other cases including (fasting blood sugar, waist, systolic blood pressure, triglyceride, HDL). Not observed between the two groups (P <0.05). Comparison of mean differences showed that in terms of FBS and total cholesterol, LDL, BPS after the intervention, a significant difference was observed between the two groups (P <0.05).
Conclusion: The results showed that the consumption of bread enriched with portulaca oleracea, was able to reduce the components associated with metabolic syndrome and improved HDL cholesterol.
Additional Files
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.